EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.
about
Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosusCurrent and emerging treatment options in the management of lupusClinical Features of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Other Connective Tissue DiseasesManagement of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future PerspectivesAdvanced and Conventional Magnetic Resonance Imaging in Neuropsychiatric LupusA model for lupus brain diseaseAnti-NR2A/B Antibodies and Other Major Molecular Mechanisms in the Pathogenesis of Cognitive Dysfunction in Systemic Lupus ErythematosusUnmet medical needs in systemic lupus erythematosusBiomarkers for CNS involvement in pediatric lupusEULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres.Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE).The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus.Current treatment of antiphospholipid syndrome: lights and shadows.The association among antioxidant enzymes, autoantibodies, and disease severity score in systemic lupus erythematosus: comparison of neuropsychiatric and nonneuropsychiatric groups.Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus.Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus.Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus.A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.Evaluation and treatment of chronic meningitis.Neuropsychiatric Symptoms in LupusBrain MRI in patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosusIncidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patientsChronic meningitis in systemic lupus erythematosus: An unusual etiologyNeuropsychiatric systemic lupus erythematosus: a diagnostic challengeThe Diagnosis and Treatment of Systemic Lupus ErythematosusImmune mediated diseases and immune modulation in the neurocritical care unitThrombosis in systemic lupus erythematosus: a review articlePeripheral neuropathies due to systemic lupus erythematosus in China.Chorea as the first and only manifestation of systemic lupus erythematosusSeizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study.Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort.Antiphospholipid-related chorea.Neuropsychiatric features of a cohort of patients with systemic lupus erythematosusImmunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.Relationship Between Clinical and Immunological Features with Magnetic Resonance Imaging Abnormalities in Female Patients with Neuropsychiatric Systemic Lupus Erythematosus.Perfusion-weighted MR imaging in cerebral lupus erythematosus.Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis.Integrative neuroscience approach to neuropsychiatric lupusUnusual aetiology of isolated lower motor neuron facial palsy: systemic lupus erythematosus presenting with cranial nerve palsy and nephritis.
P2860
Q24200954-66CA0376-DFA4-42E3-9562-E42E13FF5B5BQ26741266-63CBC6D2-CFB5-4BAD-8F91-3BD370C14016Q26773164-28025FF2-492C-4C9E-A554-653F950AE0B2Q26774815-8DF7BE60-8027-421C-853A-2F92AAED05C6Q26799922-F3235230-0D39-466F-B767-343520534EFCQ26824461-E46B4CC3-6B4D-437F-80B7-C859B677C63BQ26996498-64EC8327-7E47-4F72-A8F6-DEC9202846BBQ27005906-4FCFB7B6-1206-46A0-8213-17270B7D551EQ28082493-DC7BA946-1263-4B38-B31B-328A0D44E67FQ30886868-986B4EA9-77B5-4456-A517-1EB565A1BC56Q30900345-2FE1D61B-2421-46AD-B1F6-DB25E47E61C0Q30986945-11F77237-3787-4269-8AA0-79C3FD7E6043Q33407827-DB9E7BE1-4789-4A07-B0D3-815F0314D12BQ33423959-FC17E3C9-10F8-454F-9445-67AE35B62C0FQ33625289-D3725BC4-B133-406B-A862-3FA8217FCEF2Q33765429-B488A6D7-BCAE-48F9-BE5E-F9DF18D1BF9FQ34061733-8EA878A0-086F-4B0D-B4F4-5104EC552F69Q34114253-E174D10C-0107-4DD6-8E1B-6F3C56506E48Q34416115-F5C94977-6AA3-44FC-B25B-9CCC3A1E2B4DQ34418500-AA4A26E2-648C-4A30-B21F-A6C820754473Q34459628-003DBC4A-09F0-49B7-8554-AFD62C93413DQ34478835-C81EF0B0-9417-4298-97CC-53B36D9A4ACEQ34592686-D306223D-62B9-405E-B870-02D1E6CB5D3EQ34606866-091318C1-4370-49BA-A8DC-378FF96E4291Q35204117-B69D06FA-9D6D-4181-B3CF-7675B0084838Q35692998-52F00E03-AB44-4BFA-8FB3-78EEC1DCE634Q35729575-A5E4D7A3-2CC2-456F-A94C-B2279C3E5A54Q36147794-5BE869AD-E583-4F35-9C02-9B4ECB748F86Q36151124-9234C9CE-4F53-4CC2-9F02-5D6EE9ABB9E8Q36277546-89AD596F-789A-4906-AB1C-23F46B02A881Q36307429-55D50EF1-72E8-4160-A40F-5AC9F7E8671BQ36322289-D2BD97D9-7AAA-495D-8859-414CF921E9D1Q36337350-681A9687-6179-4655-85B4-8EF301A61170Q36440223-650883A8-ACE4-4877-8FFF-35EEC2C55F0DQ36484399-01835713-1203-4914-AAAB-B0598A0B662EQ36720077-D3A7A4E4-CD8A-42CB-84BD-4883C67011BEQ36811166-17E41DA0-2E42-4D0A-BE84-84C729331B71Q36903331-886CF938-5AA7-4D3D-AB5F-617A6639321CQ37032127-9D3D45E5-A338-4917-9CFD-35413D044348Q37145894-85F88B25-5F1C-49D2-A419-42D5145DDD64
P2860
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
EULAR recommendations for the ...... ommittee for clinical affairs.
@ast
EULAR recommendations for the ...... ommittee for clinical affairs.
@en
EULAR recommendations for the ...... ommittee for clinical affairs.
@nl
type
label
EULAR recommendations for the ...... ommittee for clinical affairs.
@ast
EULAR recommendations for the ...... ommittee for clinical affairs.
@en
EULAR recommendations for the ...... ommittee for clinical affairs.
@nl
prefLabel
EULAR recommendations for the ...... ommittee for clinical affairs.
@ast
EULAR recommendations for the ...... ommittee for clinical affairs.
@en
EULAR recommendations for the ...... ommittee for clinical affairs.
@nl
P2093
P50
P356
P1476
EULAR recommendations for the ...... ommittee for clinical affairs.
@en
P2093
C Kallenberg
D T Boumpas
G K Bertsias
I Tassiulas
M A van Buchem
P304
P356
10.1136/ARD.2010.130476
P407
P50
P577
2010-08-19T00:00:00Z